Monitor Adia Med's use of the $1,000,000 cash proceeds — the prior cross-filing indicated the funds may support an uplisting to NASDAQ and bridge financing. The equal voting structure creates potential for governance deadlock, which could slow decision-making at Adia Labs. Watch for any future 8-K disclosing the uplisting progress or additional financing.
Price Chart
Executive Summary
Adia Med, Inc. completed the sale of a 30% membership interest in its subsidiary Adia Labs LLC to Live Oak Health LLC (d/b/a QCM Biologics) for $1,500,000, consisting of $1,000,000 cash and a $500,000 promissory note. The buyer also received a two-year option to purchase an additional 10% interest for $500,000. Despite retaining 70% economic ownership, Adia Med granted the buyer equal 50% voting power, creating a deadlock governance structure. This is a capital infusion for Adia Med, but the governance concession significantly limits its control over the subsidiary.
Key Financial Metrics
Key Facts
- Adia Med sold 30% of Adia Labs LLC to Live Oak Health LLC for $1,500,000 ($1,000,000 cash + $500,000 promissory note at 7% interest, interest-only for 24 months, balloon at 48 months).
- Buyer received a two-year option to purchase 10 additional units at $50,000/unit ($500,000 total), exercisable until September 30, 2028.
- Post-closing, Adia Med holds 70% economic interest but only 50% voting power; buyer holds 30% economic interest and 50% voting power.
- The subsidiary will have two managers (one appointed by each member); deadlock resolution includes mediation and buy-sell provisions.
- Adia Labs LLC will distribute 90% of quarterly available cash (after expenses, taxes, and a 10% reserve) to members in proportion to their units.
- The filing confirms this is the completion of the deal originally announced in the August 24, 2026 8-K (engagement of Lucosky Brookman for uplisting and bridge financing).
Financial Impact
Adia Med receives $1,000,000 in immediate cash and a $500,000 note receivable. The cash can be used for corporate purposes. The sale reduces Adia Med's economic interest in Adia Labs from 100% to 70%.
Risk Factors
- Governance deadlock: equal voting power (50/50) on all major decisions could paralyze Adia Labs if members disagree.
- Buyer's option to acquire an additional 10% (for $500,000) could further dilute Adia Med's economic stake to 60% while maintaining 50% voting power.
- The $500,000 note is secured by the purchased units; default could result in Adia Med reacquiring the units but with potential legal costs and disruption.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007632 |
| Document: adia_8k.htm | 0001683168-26-007632 |
| Document: 0001683168-26-007632-index-headers.html | 0001683168-26-007632 |
| Document: 0001683168-26-007632-index.html | 0001683168-26-007632 |
| Document: 0001683168-26-007632.txt | 0001683168-26-007632 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $0.1300 | awaiting T+20 | — | $0.1100 (−15.38%) |
Oct 13, 2026 13d ago | 8-K | $0.1470 | awaiting T+20 | — | $0.1100 (−25.17%) |
Oct 5, 2026 20d ago | 8-K | $0.1480 | awaiting T+20 | — | $0.1100 (−25.68%) |
Oct 5, 2026 20d ago | 8-K | $0.1480 | awaiting T+20 | — | $0.1100 (−25.68%) |
Aug 24, 2026 9w ago | 8-K | $0.1170 $0.1450 | ▲ +23.93% | ▲ +23.92% | $0.1100 (−5.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers